Last reviewed · How we verify
Omicron-containing COVID-19 vaccine
Omicron-containing COVID-19 vaccine is a Biologic drug developed by Catholic Kwandong University. It is currently FDA-approved.
The Omicron-containing COVID-19 vaccine, developed by Catholic Kwandong University, is currently marketed but lacks detailed revenue figures and primary trial results. A key strength is the patent protection extending to 2028, which helps maintain a competitive edge in the market. The primary risk is the lack of clear differentiation from other vaccines, as detailed comparative trial data is not provided.
At a glance
| Generic name | Omicron-containing COVID-19 vaccine |
|---|---|
| Sponsor | Catholic Kwandong University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- COVID-19 Booster Study in Healthy Adults in Australia (PHASE3)
- COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (PHASE2)
- Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial (PHASE3)
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (PHASE1, PHASE2)
- Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines (PHASE2, PHASE3)
- Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines (PHASE4)
- Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines (PHASE4)
- COVID-19 Fourth Dose Study in Australia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omicron-containing COVID-19 vaccine CI brief — competitive landscape report
- Omicron-containing COVID-19 vaccine updates RSS · CI watch RSS
- Catholic Kwandong University portfolio CI